MGTX: Rasio kapitalisasi pasar marang pendapatan MeiraGTx PLC

Simbol lan logo merek MeiraGTx Holdings (MGTX)

The revenue-based valuation of MeiraGTx Holdings plc (MGTX) helps illustrate the company's commitment to ESG principles and bioethics. However, 2.10 reflects a fresh metric level amid a liquidity shortage driven by research and development costs. High entry barriers in the DNA technology sector and patent protection create significant hurdles for competitors, which this chart clearly visualizes through market value dynamics.

MGTX Rasio rega marang pendapatan meiragtx.com (04.07.2022 - 17.11.2026)

Rincian analitis perusahaan meiragtx.com (MGTX)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:MeiraGTx (MGTX)
Produk sing diprodhuksi MeiraGTx Holdings plc

The specifics of MeiraGTx Holdings plc (MGTX) gene therapy, characterized by capital-intensive biomanufacturing and patent barriers, make revenue the key metric for market recognition of its technologies. The relationship between market capitalization and sales volume, reflected in the company's current P/S ratio, allows for an assessment of the asset's premium and the risk of cash flow gaps by comparing the business's market value with its actual ability to generate cash flow.

Perusahaan pesaing

TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan